⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Lanifibranor (Lanifibranor) | 加速させる、線維化研究を

Home/Drugs/Lanifibranor

Lanifibranor

Lanifibranor

Phase 3

Sponsor: Inventiva

Indication: MASH

Mechanism of Action

Pan-PPAR Agonist

Target: PPAR-alphaTarget: PPAR-deltaTarget: PPAR-gamma

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT06126562

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

Phase:PHASE1Org:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

COMPLETED

Relevant Publications (PubMed)

Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.

Holleboom AG, Francque SM, Cusi K et al.

Metabol Open2025 Dec

Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.

Ahmed T, Farooq S, Naveed MA et al.

Cureus2025 Aug

Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease.

Patel P

J Clin Med2025 Aug 27

Antidepressant-like actions of lanifibranor and its related mechanisms in mouse models of depression: Involvement of hippocampal PPARα and BDNF.

Validated Models

This drug has been validated in the following preclinical models:

NCT03459079

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Phase:PHASE2Org:University of Florida

COMPLETEDNCT05232071

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Phase:PHASE2Org:Inventiva Pharma

COMPLETEDNCT03008070

Phase 2b Study in NASH to Assess IVA337

Phase:PHASE2Org:Inventiva Pharma

RECRUITINGNCT04849728

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Phase:PHASE3Org:Inventiva Pharma

View all trials on ClinicalTrials.gov

Wang PJ, Fan H, Jiang B et al.

Biomed Pharmacother2025 Oct

Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis.

Mangia A, Valenti LVC

Liver Int2025 Sep

View more on PubMed